BioSpace News Archive

Drug Development

AriBio Co., Ltd. Announces Topline Results from Phase 2 Study of AR1001 in Mild to Moderate Alzheimer’s Patients

AriBio, a clinical-stage biopharmaceutical company based in South Korea, announced , the topline results from its phase 2 study of AR1001 in mild to moderate Alzheimer’s disease patients.

November 4, 2021
·
4 min read
Genetown

Gamida Cell Presents Data on its NAM-Enabled NK Cell Therapies at Protein & Antibody Engineering Summit (PEGS) Europe

Gamida Cell Ltd. today announced that Aviad Pato, Ph.D., Head of Immunology Research, presented data on two nicotinamide (NAM)-enabled NK cell therapies, GDA-501 and GDA-301, at the Protein & Antibody Engineering Summit (PEGS) Europe taking place in Barcelona, Spain, and virtually November 2-4, 2021.

November 4, 2021
·
4 min read
Business

Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update

Ironwood Pharmaceuticals, Inc. today reported financial results for third quarter 2021.

November 4, 2021
·
32 min read
Business

Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021, and recent operational highlights.

November 4, 2021
·
18 min read
Business

XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events

XOMA Corporation reported its third quarter 2021 financial results and provided a recent operations update.

November 4, 2021
·
10 min read
Save the Date: Nordic Nanovector ASA to host in-person and virtual R&D Day on 30 November 2021

Nordic Nanovector ASA, a clinical stage biotechnology company developing targeted radiopharmaceuticals to extend and improve the lives of patients with haematological cancers, will host an R&D Day on Tuesday, 30 November 2021 at 14:00 CET/ 13:00 GMT/ 08:00 ET.

November 4, 2021
·
4 min read
Invitation to the presentation of Elekta’s second quarter 2021/22

Elekta invites analysts and investors to a presentation of the second quarter 2021/22 at 10:00 a.m. CET on November 25.

November 4, 2021
·
2 min read
Business

Burning Rock Collaborates with IMPACT Therapeutics to Provide Testing Services in Developing IMP9064 in both US and China

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a collaboration with IMPACT Therapeutics where Burning Rock provides testing services in connection with IMPACT Therapeutics’ development of its ATR inhibitor IMP9064

November 4, 2021
·
4 min read
Business

Active Biotech Interim report January - September 2021

We have seen the first encouraging results from the ongoing tasquinimod trial in multiple myeloma and started a new combination study with naptumomab and docetaxel in lung cancer

November 4, 2021
·
1 min read
Business

Interim report July - September 2021

Vicore Pharma Holding AB publishes the interim report for the third quarter 2021

November 4, 2021
·
6 min read